EQS-Adhoc: Kuros Biosciences AG: Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion
Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion
05-May-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Grant of European patent entitled Pharmaceutical Formulation for Use in Spinal Fusion
Schlieren (Zurich), Switzerland, May 5, 2021 - Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled Pharmaceutical Formulation for Use in Spinal Fusion . This patent claims certain matrix materials in combination with parathyroid hormone (PTH) or derivatives of PTH.
EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Patent Kuros Biosciences strengthens its patent position on use of Fibrin-PTH in spinal fusion 05-May-2021 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this anno.
About Fibrin-PTH (KUR-113)
Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog). Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques. The safety & efficacy of Fibrin PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.
Dural Sealant Market Growth to Register Steller Growth Owing openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.